Literature DB >> 30652523

Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.

Gina L Mazza1, Katie L Kunze1, Blake T Langlais1, Heidi E Kosiorek1, Todd A DeWees1, Holly L Geyer2, Robyn M Scherber3, Ruben A Mesa3, Amylou C Dueck1.   

Abstract

Administering questionnaires to patients is an efficient and effective method for assessing patients' symptoms. However, item nonresponse (skipped questions) potentially compromises the utility of these questionnaires. Using an international sample of 2,067 patients with myeloproliferative neoplasms, we evaluated the impact of item nonresponse on scoring of the Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS or MPN-10). We characterized item nonresponse on the MPN-10 and compared strategies for addressing item nonresponse (available-case analysis, proration, and multiple imputation) on the MPN-10 (multi-symptom assessment) and Brief Fatigue Inventory (BFI; single-symptom assessment). Characteristics of multi-symptom assessments would be expected to adversely affect proration, yet proration and multiple imputation provided very similar results for both the MPN-10 and BFI. This is likely because the MPN-10 item missing data rates were low, consistent with prior clinic- and internet-based studies. These results support the published scoring method for the MPN-10 (proration).

Entities:  

Keywords:  Item nonresponse; Myeloproliferative Neoplasms Symptom Assessment Form; missing data; patient-reported outcome; proration; quality of life

Year:  2019        PMID: 30652523      PMCID: PMC6594886          DOI: 10.1080/10428194.2018.1548705

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  Missing data: our view of the state of the art.

Authors:  Joseph L Schafer; John W Graham
Journal:  Psychol Methods       Date:  2002-06

2.  The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.

Authors:  T R Mendoza; X S Wang; C S Cleeland; M Morrissey; B A Johnson; J K Wendt; S L Huber
Journal:  Cancer       Date:  1999-03-01       Impact factor: 6.860

3.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

4.  Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.

Authors:  Lesley A Anderson; Glen James; Andrew S Duncombe; Ruben Mesa; Robyn Scherber; Amylou C Dueck; Frank de Vocht; Mike Clarke; Mary F McMullin
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

5.  The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.

Authors:  S J Coons; S Kothari; B U Monz; L B Burke
Journal:  Clin Pharmacol Ther       Date:  2011-10-12       Impact factor: 6.875

6.  Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Authors:  Ruben A Mesa; Jason Gotlib; Vikas Gupta; John V Catalano; Michael W Deininger; Alan L Shields; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Thomas Hare; Susan Erickson-Viitanen; William Sun; Victor Sandor; Richard S Levy; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

7.  Addressing Item-Level Missing Data: A Comparison of Proration and Full Information Maximum Likelihood Estimation.

Authors:  Gina L Mazza; Craig K Enders; Linda S Ruehlman
Journal:  Multivariate Behav Res       Date:  2015       Impact factor: 5.923

8.  Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Authors:  Robyn M Emanuel; Amylou C Dueck; Holly L Geyer; Jean-Jacques Kiladjian; Stefanie Slot; Sonja Zweegman; Peter A W te Boekhorst; Suzan Commandeur; Harry C Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Doehner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Ruben A Mesa
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

Authors:  Ruben A Mesa; Susan Schwager; Deepti Radia; Andrea Cheville; Kebede Hussein; Joyce Niblack; Animesh D Pardanani; David P Steensma; Mark R Litzow; Candido E Rivera; John Camoriano; Srdan Verstovsek; Jeffrey Sloan; Claire Harrison; Hagop Kantarjian; Ayalew Tefferi
Journal:  Leuk Res       Date:  2009-02-27       Impact factor: 3.156

Review 10.  Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Authors:  Holly L Geyer; Amylou C Dueck; Robyn M Scherber; Ruben A Mesa
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

View more
  2 in total

1.  Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.

Authors:  Gina L Mazza; Carolyn Mead-Harvey; John Mascarenhas; Abdulraheem Yacoub; Heidi E Kosiorek; Ronald Hoffman; Amylou C Dueck; Ruben A Mesa
Journal:  Lancet Haematol       Date:  2022-01       Impact factor: 30.153

2.  Managing missing items in the Fagerström Test for Nicotine Dependence: a simulation study.

Authors:  Shannon L Gutenkunst; Melanie L Bell
Journal:  BMC Med Res Methodol       Date:  2022-05-20       Impact factor: 4.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.